ENTA · Insider Trading
Enanta Pharmaceuticals, Inc
Every open-market purchase and sale reported by ENTA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | Scott T. Rottinghaus | Chief Medical Officer | F | −1,467 | −$19.57K |
| 2026-03-13 | Lesley Russell | Director | A | +20,000 deriv. | — |
| 2026-03-13 | Bruce L A Carter | Director | A | +20,000 deriv. | — |
| 2026-03-13 | Kristine Peterson | Director | A | +20,000 deriv. | — |
| 2026-03-13 | Terry Vance | Director | A | +20,000 deriv. | — |
| 2026-03-13 | Mark G Foletta | Director | A | +20,000 deriv. | — |
| 2026-03-13 | Yujiro S Hata | Director | A | +20,000 deriv. | — |
| 2026-02-13 | Scott T. Rottinghaus | Chief Medical Officer | MIXED | +3,462 | −$48.64K |
| 2026-02-13 | Matthew Paul Kowalsky | Chief Legal Officer | MIXED | +3,591 | −$27.10K |
| 2026-02-13 | Tara Lynn Kieffer | Chief Product Strategy Officer | MIXED | +3,305 | −$46.41K |
| 2026-02-13 | Brendan Luu | Chief Business Officer | MIXED | +3,305 | −$46.41K |
| 2026-02-13 | Jay R. Luly | President and CEO | MIXED | +13,845 | −$87.71K |
| 2026-02-13 | Yat Sun Or | Chief Scientific Officer | MIXED | +3,462 | −$48.64K |
| 2025-12-05 | Harry R. Trout III | See Remarks | Sell | −542 | −$7.71K |
| 2025-12-05 | Yat Sun Or | Chief Scientific Officer | Sell | −2,390 | −$34.01K |
| 2025-12-05 | Scott T. Rottinghaus | Chief Medical Officer | Sell | −798 | −$11.36K |
| 2025-12-05 | Jay R. Luly | President and CEO | Sell | −4,743 | −$67.49K |
| 2025-12-05 | Tara Lynn Kieffer | Chief Product Strategy Officer | Sell | −2,106 | −$29.97K |
| 2025-12-05 | Brendan Luu | Chief Business Officer | Sell | −1,394 | −$19.84K |
| 2025-12-05 | Kathleen S. Capps | See Remarks | Sell | −323 | −$4.60K |
| 2025-12-03 | Harry R. Trout III | See Remarks | MIXED | −485 | −$6.79K |
| 2025-12-03 | Yat Sun Or | Chief Scientific Officer | F | −753 | −$10.63K |
| 2025-12-03 | Brendan Luu | Chief Business Officer | F | −498 | −$7.03K |
| 2025-12-03 | Jay R. Luly | President and CEO | F | −1,885 | −$26.62K |
| 2025-12-03 | Tara Lynn Kieffer | Chief Product Strategy Officer | F | −753 | −$10.63K |
| 2025-12-03 | Kathleen S. Capps | See Remarks | MIXED | −292 | −$4.09K |
| 2025-11-26 | Scott T. Rottinghaus | Chief Medical Officer | A | +110,000 deriv. | — |
| 2025-11-26 | Matthew Paul Kowalsky | Chief Legal Officer | A | +90,000 deriv. | — |
| 2025-11-26 | Jay R. Luly | President and CEO | A | +310,000 deriv. | — |
| 2025-11-26 | Brendan Luu | Chief Business Officer | A | +90,000 deriv. | — |
| 2025-11-26 | Tara Lynn Kieffer | Chief Product Strategy Officer | A | +100,000 deriv. | — |
| 2025-11-26 | Yat Sun Or | Chief Scientific Officer | A | +110,000 deriv. | — |
| 2025-11-26 | Kathleen S. Capps | See Remarks | A | +3,163 | — |
| 2025-11-26 | Harry R. Trout III | See Remarks | A | +6,463 | — |
| 2025-08-08 | Scott T. Rottinghaus | Chief Medical Officer | F | −2,217 | −$15.50K |
| 2025-03-14 | Kristine Peterson | Director | A | +15,700 deriv. | — |
| 2025-03-14 | Bruce L A Carter | Director | A | +15,700 deriv. | — |
| 2025-03-14 | Terry Vance | Director | A | +15,700 deriv. | — |
| 2025-03-14 | Lesley Russell | Director | A | +15,700 deriv. | — |
| 2025-03-14 | Mark G Foletta | Director | A | +15,700 deriv. | — |
| 2025-03-14 | Yujiro S Hata | Director | A | +15,700 deriv. | — |
| 2025-02-14 | Yat Sun Or | Chief Scientific Officer | MIXED | +5,426 | −$24.17K |
| 2025-02-14 | Tara Lynn Kieffer | Chief Product Strategy Officer | MIXED | +4,174 | −$18.59K |
| 2025-02-14 | Brendan Luu | Chief Business Officer | MIXED | +4,174 | −$18.59K |
| 2025-02-14 | Paul J Mellett | Chief Fin. & Admin Officer | MIXED | +4,174 | −$18.59K |
| 2025-02-14 | Jay R. Luly | President and CEO | MIXED | +18,016 | −$41.84K |
| 2025-02-14 | Scott T. Rottinghaus | Chief Medical Officer | MIXED | +6,889 | −$15.99K |
| 2025-02-12 | Jay R. Luly | President and CEO | Buy | +45,000 | +$256.05K |
| 2024-12-10 | Jay R. Luly | President and CEO | Sell | −5,142 | −$41.44K |
| 2024-12-10 | Scott T. Rottinghaus | Chief Medical Officer | Sell | −866 | −$6.98K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jay R. Luly | President and CEO | 862,826 | $9.70M |
| Yat Sun Or | Chief Scientific Officer | 378,267 | $4.25M |
| Paul J Mellett | Chief Fin. & Admin Officer | 95,884 | $1.08M |
| Brendan Luu | Chief Business Officer | 39,904 | $448.52K |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 33,925 | $381.32K |
| Scott T. Rottinghaus | Chief Medical Officer | 23,787 | $267.37K |
| Harry R. Trout III | See Remarks | 16,348 | $183.75K |
| Kathleen S. Capps | See Remarks | 8,377 | $94.16K |
| Terry Vance | Director | 5,800 | $65.19K |
| Matthew Paul Kowalsky | Chief Legal Officer | 5,493 | $61.74K |
| Bruce L A Carter | Director | 807 | $9.07K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ENTA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.